1. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. Issue 3 (March 2022) Authors: Kremsner, Peter G; Ahuad Guerrero, Rodolfo Andrés; Arana-Arri, Eunate; Aroca Martinez, Gustavo Jose; Bonten, Marc; Chandler, Reynaldo; Corral, Gonzalo; De Block, Eddie Jan Louis; Ecker, Lucie; Gabor, Julian Justin; Garcia Lopez, Carlos Alberto; Gonzales, Lucy; Granados González, María Angélica; G... Journal: Lancet infectious diseases Issue: Volume 22:Issue 3(2022) Page Start: 329 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗